Radiotheranostics Market Current Trends and Future Scope Analysis Report [Yahoo! Finance]
Actinium Pharmaceuticals, Inc. (Delaware) (ATNM)
NASDAQ:AMEX Investor Relations:
ir.actiniumpharma.com
Company Research
Source: Yahoo! Finance
AG, Spectrum Pharmaceuticals, Inc., Ipsen S.A., Actinium Pharmaceuticals, Inc. (ATNM), Nordic Nanovector ASA, Y-mAbs Therapeutics, Inc., Sofie Biosciences, Inc., Terumo Corporation, Sirtex Medical Limited, Boston Scientific Corporation, Nihon Medi-Physics, ITM Isotopen Technologien München AG, Advanced Accelerator Applications, Telix Pharmaceuticals, Theragnostics Ltd., NuView Life Sciences, Jubilant Pharma Limited, and Clarity Pharmaceuticals Jersey City, NJ, Jan. 30, 2024 (GLOBE NEWSWIRE) -- “ Radiotheranostics Market ” in terms of revenue was estimated to be worth $1.84 billion in 2023 and is poised to reach $4.36 billion by 2031, growing at a CAGR of 11.58% from 2024 to 2031 according to a new report by InsightAce Analytic. Latest Drivers Restraint and Opportunities Market Snapshot: Key factors influencing the global radiotheranostics market are: Technological advancement Increasing awareness Increasing Cancer Rate The following are the primary obstacles to the radio
Show less
Read more
Impact Snapshot
Event Time:
ATNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATNM alerts
High impacting Actinium Pharmaceuticals, Inc. (Delaware) news events
Weekly update
A roundup of the hottest topics
ATNM
News
- Radiopharma stocks higher as sector welcomes the latest M&A deal [Seeking Alpha]Seeking Alpha
- Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual MeetingPR Newswire
- Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant AnnuaAcquire Media Monitor
- Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant AnnuaPR Newswire
- Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy [Yahoo! Finance]Yahoo! Finance
ATNM
Earnings
- 8/14/23 - Miss
ATNM
Sec Filings
- 4/26/24 - Form 10-Q
- 3/29/24 - Form S-8
- 3/29/24 - Form 10-K
- ATNM's page on the SEC website